[1]Saxty,Gordon;Woodhead,StevenJ.;Berdini,Valerio;Davies,ThomasG.;Verdonk,MarcelL.;Wyatt,PaulG.;Boyle,RobertG.;Barford,David;Downham,Robert;Garrett,MichelleD.;Carr,RobinA.[JournalofMedicinalChemistry,2007,vol.50,#10,p.2293-2296]
[2]CurrentPatentAssignee:UNIVERSITYOFLONDON;OTSUKAHOLDINGSCOLTD;CANCERRESEARCHUK-US2010/166699,2010,A1
[1]Saxty,Gordon;Woodhead,StevenJ.;Berdini,Valerio;Davies,ThomasG.;Verdonk,MarcelL.;Wyatt,PaulG.;Boyle,RobertG.;Barford,David;Downham,Robert;Garrett,MichelleD.;Carr,RobinA.[JournalofMedicinalChemistry,2007,vol.50,#10,p.2293-2296]
[1]Saxty,Gordon;Woodhead,StevenJ.;Berdini,Valerio;Davies,ThomasG.;Verdonk,MarcelL.;Wyatt,PaulG.;Boyle,RobertG.;Barford,David;Downham,Robert;Garrett,MichelleD.;Carr,RobinA.[JournalofMedicinalChemistry,2007,vol.50,#10,p.2293-2296]
Title: AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Journal: Molecular cancer therapeutics 20100501
Title: Identification of inhibitors of protein kinase B using fragment-based lead discovery.
Journal: Journal of medicinal chemistry 20070517
Title: Grimshaw KM, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther, 2010, 9(5), 1100-1110.